Início › Leucemia Mieloide Aguda › Oregon
Ensaios clínicos de Leucemia Mieloide Aguda em Oregon
27 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Oregon.
Cidades em Oregon
Texto oficial do estudo (Inglês)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- e mais 7
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT03874052Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
RecrutandoFase 3
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Oregon Health & Science University, Portland
RecrutandoFase 1/2
30 Days · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04065399Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- OHSU Knight Cancer Institute, Portland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06504459Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Oregon Health and Science University, Portland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT03471260Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Portland OR-OHSU, Portland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Doernbecher Children's Hospital, Portland
RecrutandoFase 3
29 Days – 21 Years · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Willamette Valley Cancer Institute, Eugene
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07007312Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
RecrutandoFase 3
Idades de 18 a 75 · Todos os sexos · Atualizado em 17 de jul. de 2026 · NCT05429632Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 14 de jul. de 2026 · NCT04659616Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RecrutandoFase 2
Idades de 18 a 65 · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT07228273Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de jul. de 2026 · NCT07216443Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- OHSU Knight Cancer Institute, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT07548983A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jun. de 2026 · NCT06357182A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Oregon Health and Science University, Portland
- Oregon Oncology Specialists, Salem
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de abr. de 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
RecrutandoFase 2
Idades de 18 a 66 · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06859424A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- OHSU, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de fev. de 2026 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Oregon Health & Science University, Portland
RecrutandoVoluntários saudáveis bem-vindos
Idades de 18 a 120 · Todos os sexos · Atualizado em 25 de jul. de 2025 · NCT05237258Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.